DOST Form 2 (for Basic/Applied Research)

DETAILED RESEARCH & DEVELOPMENT PROJECT PROPOSAL

(1) PROJECT PROFILE
Program Title: BS Chemistry
Project Title: Anti-inflammatory activity of Red Gumamela (Hibiscus rosa-sinensis Linn) extracts through
Carrageenan-induced paw edema
Project Leader/Sex: James Vincent C. Santiago/Male
Project Duration (number of months): 12 Months
Project Start Date: June 2023
Project End Date: June 2024
Implementing Agency (Name of University-College-Institute, Department/Organization or Company):
Polytechnic University of the Philippines - Manila, Department of Physical Science
Address/Telephone/Fax/Email (Barangay, Municipality, District, Province, Region): Sta. Mesa, Manila, 1st District,
Metro Manila, National Capital Region/jamessantiago242424@gmail.com
(2) COOPERATING AGENCY/IES (Name/s and Address/es)

(3) SITE(S) OF IMPLEMENTATION

IMPLEMEN COUNTRY REGION PROVINCE DISTRICT MUNICIPALITY BARANGAY
TATION
SITES NO.
1. Philippines National Metro 1st Manila Sta. Mesa
Capital Manila
Region
2.
3.
4.
5.

(4) TYPE OF RESEARCH (5) R&D PRIORITY AREA & PROGRAM (based on
_____ Basic HNRDA 2017-2022)
_____ Applied _____ Agriculture, Aquatic and Natural Resources
Commodity: ________________
_____ Health
Priority Topic: ________________
_____ Industry, Energy and Emerging Technology
Sector: ________________
_____ Disaster Risk Reduction and Climate
Change Adaptation
_____ Basic Research
Sector: ________________

Sustainable Development Goal (SDG)

Addressed 3. Good Health and Well Being

(6) EXECUTIVE SUMMARY (not to exceed 200 words)

In modern times, pills and medicine are used to treat different diseases and illnesses, but before it
became the medicine we know, traditional way of treating illnesses is done with different medicinal plants.
These medicinal plants have certain uses, such as for inflammation, antioxidant, antimicrobial, antifungal,
and such. In the Philippines, one of the known medicinal plants is the red gumamela, which is commonly
used for swelling. Red gumamela are reported to be having different phytochemicals that are responsible
for its anti-inflammatory activity. In this study, red gumamela extract is subjected to carrageenan-induced
paw edema to identify its reversibility against inflammation. Different concentration of red gumamela
extract are assessed to identify whether it has effect on the anti-inflammatory activity of red gumamela
.
(7) INTRODUCTION

Plants have been widely used as an aid for healing different diseases since ancient times [1]. The
practice of using plants for treating illness led to the different forms of modern medicine available today
[2]. As technology arises, comprehensive methods were discovered to analyze different medicinal plants.
Medicinal plants are also found to contain phytochemicals with huge biological impacts [3]. One of the
known medicinal plants in the Philippines is the red gumamela or Hibiscus rosa-sinensis Linn. Red
gumamela is a glabrous shrub commonly found in tropics [4]. It is a plant from the family Malvaceae,
genus Hibiscus, and species Hibiscus rosa sinensis [5,6]. gumamela comes in an array of variants with
different colored flowers but the red one is the commonly utilized one in medicine [7].
 (7.1) RATIONALE/SIGNIFICANCE (not to exceed 300 words)

In the Philippines, more than 12,000 species of flora are identified and around 1500 were known to be
used as traditional medicine [8]. However, only 120 plants are scientifically validated for safety and
efficacy [9]. The study will provide data that could help on further explaining the anti-inflammatory activity
of the red gumamela and increasing the number of validated plants for pharmaceutical applications in the
Philippines

(7.2) SCIENTIFIC BASIS/THEORETICAL FRAMEWORK

Red gumamela is traditionally used for regulating menstruation and blood pressure, treating liver
disorders and stomach pains, as well as arthritis, boils, and coughs [10,11]. This characteristic of red
gumamela is due to the phytochemicals found in the plant itself. The presence of carbohydrates,
alkaloids, flavonoids, saponins, proteins, and amino acids are found in the red gumamela through various
tests [12]. These phytochemicals are known to have specific therapeutic activity.

(7.3) OBJECTIVES

General: To assess the anti-inflammatory activity of Hibiscus rosa-sinensis Linn

Specific: To show the effectiveness of using Hibiscus rosa-sinensis Linn as an anti-inflammatory agent

(8) REVIEW OF LITERATURE

In understanding medicinal plants, several methods are used to validate and assess the biological
phenomena that occur after using medicinal plants. Before, the trial-and-error method was used to
identify whether a plant showed healing properties or not [13]. This method is undeniably dangerous as
toxic plants might be used further compromising the health of the user. In time, modern science, which
started during the Renaissance, helped in furthering the understanding of medicinal plants through
various chemical analyses associated with different instruments [14]. In the 18th century, many plants
were analyzed; their properties, side effects, and method of treatment were identified, but not the active
compound causing the activity [15]. The recorded findings from different analyses of medicinal plants
helped to emerge and develop the known drugs and pills of today [16]. As time goes by, technology is
utilized to identify what causes the specific biological activity, which is the phytochemicals.

Phytochemicals are bioactive compounds that possess health benefits, commonly derived from plants
[17,18]. These phytochemicals are known to have specific therapeutic activity. The therapeutic activities
found in red gumamela are anti-inflammatory [19-24], anticoagulant [19], antimicrobial [20-21,23-24], anti-
thrombotic [19,30], anti-aging [20], cardioprotective [20] anti-oxidant [20-22,24], anticancer [21,23],
antidiabetic [21], and antiviral [24]. From the phytochemicals found in red gumamela, most are identified
to have an anti-inflammatory activity.

(9) METHODOLOGY

The plant sample that will be used in the experiment will be bought from a botanical garden. To verify and
authenticate the plant, a sample specimen will be sent to the University of the Philippines - Diliman,
Institute of Biology for analysis. Once the bought sample is authenticated as Hibiscus rosa-sinensis Linn,
the experiment will be further continued.

The plant sample will be extracted after air-drying. The dried plant sample will undergo a powdering
process. Once the plant sample is powdered and is enough for experimentation, it will be extracted.
Maceration will be the extraction method that will be used for this study. In this process, the powdered
plant sample will be placed in a stoppered container along with the solvent that will be used [25,26]. The
solvent used for this extraction is 50% ethanol. Frequent agitation of the container is also done to dissolve
the extract faster. The extraction method will be done three times to make sure all of the soluble
phytochemicals are extracted. After the extraction filtration will be done under vacuum using a Buchner
funnel lined up with Whatman no.1 filter paper to properly eliminate the undissolved particles from the
maceration. The removed alcoholic extract will then be put in a rotary evaporator to remove the alcohol in
the solution leaving the flask with the pure extracts.

The extracted solution will undergo different qualitative phytochemical screening to identify whether the
extract contains the reported phytochemicals it possesses, which are alkaloids, flavonoids, saponins,
carbohydrates, amino acids, and proteins.

The bioassay that will be used in the study is the Carrageenan-induced paw edema. Carrageenan
induced paw edema is a test commonly facilitated to identify the amount of reversibility of drugs or
medicinal plants against inflammation. Carrageenan-induced inflammation has significant predictive value
for anti-inflammatory drugs working through mediators of acute inflammation because it is useful for
identifying orally active anti-inflammatory medicines [27].
 The experimentation process will follow the method described by Raduan et al. [28] with slight
modification. Before the anti-inflammatory activity test, 12 mice subjects will be randomly grouped into
four groups representing the control group and different concentrations of red gumamela extracts. The
three concentrations of gumamela extracts that will be used are 100 mg/kg, 300 mg/kg, and 500 mg/kg.
After the groupings, the right paw of each mouse is measured using a phetlysmometer and recorded as
initial paw volume. Once all the mice have initial paw reading, 0.1 mL carrageenan will be injected to the
right-hand paw of the mice. After 30 minutes, each group will receive the red gumamela extract with
varying concentration and distilled water (for control group) via injecting to the same paw. The paw of
each mouse will be measured from 1st to 6th hour from the time the extract and distilled water through
the phetlysmometer.

(10) TECHNOLOGY ROADMAP Not Applicable

(11) EXPECTED OUTPUTS (6Ps)

Publication - Once the study obtains results, it will be submitted to various publication journals or
websites that could be accessible for students aiming to replicate the same study.
Patent/Intellectual Property - No patent is expected to be obtained in this research.
Product - The study expects a published and validated paper on the anti-inflammatory activity of red
gumamela extract
People Service - Once the study on the anti-inflammatory activity of red gumamela extract gained
success, it expects to contribute to the scientific community of the Philippines in terms of knowledge and
information that is needed to understand red gumamela and its anti-inflammatory activity.
Place and Partnership - The place where all the works will be done is the Polytechnic University of the
Philippines. Partnership with the Department of Science and Technology is also expected. Partnerships
and deals that will be done will help in funding the study to obtain success in the study.
Policy - No science-based policy is expected to be obtained in the study.

(12) POTENTIAL OUTCOMES

The success of this study will emerge different studies on the bioactivities of red gumamela. It is also
expected that once the study becomes successful different methods on extracting the red gumamela to
obtain higher yields on different bioactivities.

(13) POTENTIAL IMPACTS (2Is)

Social Impact – Once the study became successful, it is expected to be produce better methods in
extracting red gumamela for traditional use, since some people are inclined on traditional medicine than
those of commercially produced medicine.
Economic Impact – Once the study obtains optimal results, different pharmaceutical companies will use
the data obtained in the study to produce pills and medicine derived from red gumamela for inflammation.

(14) TARGET BENEFICIARIES

The scientific community of the Philippines - Once the study earns success and attention to the scientific
community, it can help to produce research on about anti-inflammatory activity of different medicinal plant
using the same methods or with minimal changes

(15) SUSTAINABILITY PLAN

Funding is expected for the study to work. Transparency on the given fund will be done as the research
goes along. Materials that are bought will be ensured to be fully utilized. No harm in the environment will
be done throughout the study.

(16) GENDER AND DEVELOPMENT (GAD) SCORE (refer to the attached GAD checklist)

The Gender and Development Score of the study is 4.83, meaning the proposed project has GAD
prospects. The study gaining low GAD score is due to the fact that the study aims to further scientific
furtherance. However, the proponents of the research will make sure to implement the necessary GAD
related measures all the way to the end of the study.

(17) LIMITATIONS OF THE PROJECT

The limitation of this study is it focuses only on the reversibility of the red gumamela extract on the
carrageenan-induced inflammation at different concentration. It does not cover different extraction
techniques to yield better results.
(18) LIST OF RISKS AND ASSUMPTIONS RISK MANAGEMENT PLAN

Since the experimentation will be done in a laboratory, necessary PPE will be worn throughout the
experimentation process. Researchers are also obligated to be aware of laboratory safety procedures in
case there will be conflict during the experimentations.

(19) LITERATURE CITED

[1] Petrovska, B. (2012). Historical review of medicinal plants' usage. Pharmacognosy Reviews, 6(11), 1.
doi:10.4103/0973-7847.95849
[2] Salmerón-Manzano, E., Garrido-Cardenas, J. A., & Manzano-Agugliaro, F. (2020). Worldwide
Research Trends on Medicinal Plants. International Journal of Environmental Research and Public
Health, 17(10), 3376. doi:10.3390/ijerph17103376
[3] Mahesh Venkata Krishna, & Karthika Bahulayan Arun. (2020). Antidiabetic Phytochemicals and Their
Applications in Modern Medicine. Springer EBooks, 259–277. https://doi.org/10.1007/978-981-15-1761-
7_11
[4] Upadhyay, S., & Upadhyay , P. (2011). Hibiscus rosa-sinensis: Pharmacological review . International
Journal of Research in Pharmaceutical and Biomedical Sciences, 2(4), 1449–1450.
[5] Pekamwar SS, Kalyankar TM, Jadhav AC. Hibiscus rosa-sinensis: A review on ornamental
plant. World Journal of Pharmacy and Pharmaceutical Sciences. 2013;2(6):4719-27.
[6] ITIS, Hibiscus rosa-sinensis, https://www.itis.gov/ servlet/SingleRpt/ SingleRpt?
search_topic=TSN&search_value=21616#null
[7] Jadhav, V. M., et al. “Hibiscus Rosa Sinensis Linn – ““Rudrapuspa”” : A Review.” Journal of Pharmacy
Research 2009, vol. 2, no. 7, July 2009.
[8] Cruz P, Ramos A. Indigenous Health Knowledge Systems in the Philippines: A Literature Survey.
XIIIth CONSAL Conference, Manila, Philippines. Manila. 2006;(1)
[9] Eusebio J, Umali B. Inventory, documentation and status of medicinal plants research in the
Philippines. Medicinal Plants Research in Asia, Volume 1: The framework and project work plans. In
Batugal, A., Kanniah, J., Young, L.S. & Oliver, J. edition. International Plant Genetic Research Institute-
Regional Office of Asia, the Pacific and Oceana (IPGRI-APO), Serdang, Selangor, DE, Malaysia; 2004
[10] Kumar, A., & Singh, A. (2012). Review on Hibiscus rosa sinensis.
[11] Khristi, V., & Patel, V. H. (2017). THERAPEUTIC POTENTIAL OF HIBISCUS ROSA SINENSIS: A
REVIEW. International Journal of Nutrition and Dietetics, 4(2), 105–123.
https://doi.org/10.17654/nd004020105.
[12] Gupta, V, et al. Pharmacopoeial Standardization of Hibiscus Rosa Sinensis Linn. Jan. 2009.
[13] Kunle. (2012). Standardization of herbal medicines - A review. International Journal of Biodiversity
and Conservation, 4(3). doi:10.5897/ijbc11.163
[14] Reeds, K. M. (1976). Renaissance humanism and botany. Annals of Science, 33(6), 519–542.
doi:10.1080/00033797600200481
[15] Faridi, P., Zarshenas, M. M., Abolhassanzadeh, Z., & Mohagheghzadeh, A. (2010). Collection and
storage of medicinal plants in The Canon of Medicine. Pharmacognosy Journal, 2(8), 216–218.
doi:10.1016/s0975-3575(10)80096-3
[16] Arceusz, A., Radecka, I., & Wesolowski, M. (2010). Identification of diversity in elements content in
medicinal plants belonging to different plant families. Food Chemistry, 120(1), 52–58.
doi:10.1016/j.foodchem.2009.09.068
[17] Higdon, J. V., & Drake, V. J. (2013). An Evidence-based Approach to Phytochemicals and Other
Dietary Factors. https://doi.org/10.1055/b-002-76301.
[18] Si, H., & Liu, D. (2014). Dietary antiaging phytochemicals and mechanisms associated with
prolonged survival. The Journal of Nutritional Biochemistry, 25(6), 581–591.
https://doi.org/10.1016/j.jnutbio.2014.02.001
[19] Michelle Kilcoyne, & Lokesh Joshi. (2007). Carbohydrates in Therapeutics. Cardiovascular &
Hematological Agents in Medicinal Chemistry , 5(3), 186–197. doi:10.2174/187152507781058663
[20] Jucá, M. M., Cysne Filho, F. M. S., de Almeida, J. C., Mesquita, D. da S., Barriga, J. R. de M., Dias,
K. C. F., … Vasconcelos, S. M. M. (2018). Flavonoids: biological activities and therapeutic potential.
Natural Product Research, 1–14. doi:10.1080/14786419.2018.1493588
[21] Gutiérrez-Grijalva, E. P., López-Martínez, L. X., Contreras-Angulo, L. A., Elizalde-Romero, C. A., &
Heredia, J. B. (2020). Plant Alkaloids: Structures and Bioactive Properties. Plant-Derived Bioactives, 85–
117. doi:10.1007/978-981-15-2361-8_5
[22] Santiago, L.Â.M., Neto, R.N.M., Santos Ataíde, A.C. et al. Flavonoids, alkaloids and saponins: are
these plant-derived compounds an alternative to the treatment of rheumatoid arthritis? A literature review.
Clin Phytosci 7, 58 (2021). https://doi.org/10.1186/s40816-021-00291-3
[23] Wang, L., Wang, N., Zhang, W. et al. Therapeutic peptides: current applications and future directions.
Sig Transduct Target Ther 7, 48 (2022). https://doi.org/10.1038/s41392-022-00904-4
[24] Leader, B., Baca, Q. & Golan, D. Protein therapeutics: a summary and pharmacological
classification. Nat Rev Drug Discov 7, 21–39 (2008). https://doi.org/10.1038/nrd2399
[25] Rasul, M. G. (2018). Conventional Extraction Methods Use in Medicinal Plants, their Advantages and
Disadvantages. International Journal of Basic Sciences and Applied Computing (IJBSAC), 2(6), 10–14.
[26] Suckdev Swami Handa, Suman Preet Singh Khanuja, Gennaro Longo, Dev Dutt Rakesh, United
Nations Industrial Development Organization, & International Centre For Science And High Technology.
(2008). Extraction technologies for medicinal and aromatic plants. Earth, Environmental And Marine
Sciences And Technologies.
[27] Vinegar, R., Schreiber, W., Hugo, R., 1969. Biphasic development of carrageenan edema in rats. J.
Pharmacol. Exp. Ther. 66, 96–100.
[28] Raduan, S., Aziz, M. A., Roslida, A., Zakaria, Z., Zuraini, A., & Hakim, M. (2013). Anti- inflammatory
effects of Hibiscus rosa-sinensis L. and Hibiscus rosa-sinensis var. alba ethanol extracts. International
Journal of Pharmacy and Pharmaceutical Sciences, 5(4).

(20) PERSONNEL REQUIREMENT

Percent Time
Position Devoted to the Responsibilities
Project

(21) BUDGET BY IMPLEMENTING AGENCY

IMPLEMENTING AGENCY PS MOOE EO Total
Year 1
Year 2
Year n
TOTAL
(22) OTHER ONGOING PROJECTS BEING HANDLED BY THE PROJECT LEADER: _____ (number)
Involvement in the
Title of the Project Funding Agency Project

(23) OTHER SUPPORTING DOCUMENTS (Please refer to page 2 for the additional necessary documents.)

I hereby certify the truth of the foregoing and have no pending financial and/or technical
obligations from the DOST and its attached Agencies. I further certify that the programs/projects
being handled is within the prescribed number as stipulated in the DOST-GIA Guidelines. Any
willful omission/false statement shall be a basis of disapproval and cancellation of the project.

SUBMITTED BY (Project Leader) ENDORSED BY (Head of the Agency)

Signature

Printed Name JAMES VINCENT C. SANTIAGO

Designation/Title RESEARCHER

Date May 15, 2023

Note: See guidelines/definitions at the back.
 DOST Form 2 (for Basic/Applied Research)
DETAILED R & D PROJECT PROPOSAL

I. General Instruction: Submit through the DOST Project Management Information System (DPMIS),
http://dpmis.dost.gov.ph, the detailed R&D proposal for the component project
together with the detailed proposal of the whole Program, project workplan, line-
item budget (LIB), 1-page curriculum vitae of the Project Leader, and Certificate
of Incorporation or DTI Registration (if applicable) and other applicable supporting
documents required under item II.23 below. Also, submit four (4) copies of the
proposal together with its supporting documents. Use Arial font, 11 font size.

II. Operational Definition of Terms:

1. Title- the identification of the Program and the component projects.

Project- refers to the basic unit in the investigation of specific S&T problem/s with predetermined
objective/s to be accomplished within a specific time frame.

Project Leader- refers to a project’s principal researcher/implementer.

Project Duration- refers to the grant period or timeframe that covers the approved start and
completion dates of the project, and the number of months the project will be implemented.

Implementing Agency- the primary organization involved in the execution of a program/project

which can be a public or private entity

2. Cooperating Agency/ies- refers to the agency/ies that support/s the project by participating in its
implementation as collaborator, co-grantor, committed adopter of resulting technology, or potential
investor in technology development or through other similar means.

3. Site/s of Implementation- location/s where the project will be conducted. Indicate the barangay,
municipality, district, province, region, and country.

4. Type of Research- indicates whether the project is basic or applied.

Basic research- is an experimental or theoretical work undertaken primarily to acquire new
knowledge of the underlying foundations of phenomena and observable facts, without any
particular or specific application or use in view.
Applied research- is an investigation undertaken in order to utilize data/information gathered from
fundamental/basic researches or to acquire new knowledge directed primarily towards a specific
practical aim or objective with direct benefit to society.

5. R&D Priority Area and Program- based on the Harmonized National R&D Agenda 2017-2022,
indicates which R&D agenda the project can be categorized in: Agriculture, Aquaculture and Natural
Resources; Health; Industry, Energy, and Emerging Technology; Disaster Risk Reduction and Climate
Change Adaptation; and Basic Research. Indicate also the specific Commodity/Sector, whether crops,
livestock, forestry, agricultural resources or socio-economics; fisheries or aquatic resources;
biotechnical, pharmaceutical, or health services; biotechnology, information technology, material
science, photonics or space technology; industry, energy, utilities or infrastructure.

Sustainable Development Goal (SDG) Addressed- indicates which among the 17 SDGs adopted
by the United Nations Members States are addressed by the project

6. Executive Summary- briefly discusses what the whole proposal is about

7. Introduction- a formally written declaration of the project and its idea and context to explain the
goals and objectives to be reached and other relevant information that explains the need for the
project and aims to describe the amount of work planned for implementation; refers to a simple
explanation or depiction of the project that can be used as communication material.

7.1. Rationale- brief analysis of the problems identified related to the project
Significance- refers to the alignment to national S&T priorities, strategic relevance to national
development and sensitivity to Philippine political context, culture, tradition and gender and development.

7.2. Scientific Basis- other scientific findings, conclusions or assumptions used as justification for
the research
Theoretical Framework- the structure that summarizes concepts and theories that serve as
basis for the data analysis and interpretation of the research data.
 7.3. Objectives- statements of the general and specific purposes to address the problem areas of
the project.

8. Review of Literature- refers to the following: (a) related researches that have been conducted,
state-of-the-art or current technologies from which the project will take off; (b) scientific/technical merit;
(c) results of related research conducted by the same Project Leader, if any; (d) Prior Art Search, and;
(e) other relevant materials.

9. Methodology- discusses the following: (a) variables or parameters to be measured and evaluated
or analyzed; (b) treatments to be used and their layout; (c) experimental procedures and design; (d)
statistical analysis; (e) evaluation method and observations to be made, strategies for implementation
(Conceptual/Analytical framework).

10. Technology Roadmap (if applicable)- a visual document that communicates the plan for
technology. It is a flexible planning technique to support strategic and long-range planning by
matching short- and long-term goals to specific technology solutions.

11. Expected Outputs (6Ps)- deliverables of the project based on the 6Ps metrics (Publication,
Patent/Intellectual Property, Product, People Service, Place and Partnership, and Policy).
Publication- published aspect of the research, or the whole of it, in a scientific journal or conference
proceeding for peer review, or in a popular form.
Patent/Intellectual Property- proprietary invention or scientific process for potential future profit.
Product- invention with a potential for commercialization.
People Service- people or groups of people, who receive technical knowledge and training.
Place and Partnership- linkage forged because of the study.
Policy- science-based policy crafted and adopted by the government or academe as a result of the
study.

12. Potential Outcomes- refer to the result that the proponent hopes to deliver three (3) years after
the successful completion of the project.

13. Potential Impacts

Social Impact- refers to the effect or influence of the project to the reinforcement of social ties
and building of local communities.
Economic Impact- refers to the effect or influence of the project to the commercialization of its
products and services, improvement of the competitiveness of the private sector, and local,
regional, and national economic development.

14. Target Beneficiaries- refers to groups/persons who will be positively affected by the conduct of
the project.

15. Sustainability plan- refers to the continuity of the project or how it shall be operated amidst
financial, social, and environmental risks.

16. Gender and Development (GAD) Score- refers to the result of accomplishing GAD checklists (for
project monitoring and evaluation/project management and implementation) to highlight the
contribution of the project in the achievement of the objectives of Republic Act 7192, “Women in
Development and Nation Building Act,” interpreted as gender-responsive, gender-sensitive, has
promising GAD concepts, or GAD is invisible.

17. Limitations of the Project- refer to restrictions or constraints in the conduct of the project.

18. Risk- refers to an uncertain event or condition that its occurrence has a negative effect on the
project.
Assumption- refers to an event or circumstance that its occurrence will lead to the success of the
project.

19. Literature Cited- an alphabetical list of reference materials (books, journals and others) reviewed.
Use standard system for citation.

20. Personnel Requirement- details on the position of personnel to be involved in the project, percent
time devoted to the project, and responsibilities.

21. Budget By Implementing Agency- personnel services (PS), maintenance and other operating
expenses (MOOE), and equipment outlay (EO) requirement of the project by implementing agency for
 Year 1 and for the whole duration of the project. Please refer to the DOST-GIA Guidelines for the
details (Section IX.B of DOST Administrative Order (A.O.) 011, s. 2020).
a. PS- total requirement for wages, salaries, honoraria, additional hire and other personnel
benefits.

b. MOOE- total requirement for supplies and materials, travel expenses, communication, and
other services.

c. EO- total requirement for facilities and equipment needed by the Program.

22. Other Ongoing Projects Being Handled By the Project Leader- list of ongoing projects being
handled by the Project Leader funded by the DOST-GIA Program and other sources, and the
accompanying responsibilities relevant to the project.

23. Other supporting documents required- as stated in Section VII of DOST A.O. No. 011, Series of
2020 – Revised Guidelines for the Grants-in-Aid Program:
a. Detailed breakdown of the required fund assistance to indicate the counterpart of the
proponent and other fund sources including letter/s of commitment from the implementing,
collaborating and coordinating agency/entity/ies;1
b. A counterpart fund, in kind and/or in cash, shall be required from the implementing
agency/entity as one of the application requirements. All projects must have a minimum of 15%
counterpart contribution except for projects involving public good;1
c. Curriculum Vitae or Personal Data Sheet (PDS) of Project Leader and other co-
researchers/implementers. The service record may be requested if needed;1
d. Clearance from the DOST or the Funding Agency (e.g., DOST Councils) on previously funded
completed projects handled by the Project Leader;1
e. Approval from the institution’s ethics review board for research involving human subjects or in
the case of animal subjects, approval from the Bureau of Animal Industry (BAI) (for PCAARRD-
and PCHRD-monitored projects);
f. Clearance from the DOST Biosafety Committee (DOST-BC) shall be required for research
proposals involving the use of GMOs under contained use (i.e., experiments done in
laboratories, screen house, green house). For projects other than contained use, they shall be
referred to the appropriate agency. The DOST Sectoral Councils, after determination as to
whether or not the proposal has biosafety implications, shall endorse the same to the DOST-
BC in accordance with the prescribed format under Annex 3 of the Philippine Biosafety
Guidelines for Contained Use of Genetically Modified Organisms (series of 2014) (if
applicable); and
g. For the private non-profit/non-government/people’s organizations and startups:
i. Up-to-date Securities and Exchange Commission (SEC) registration, or Department
of Trade and Industry (DTI) registration, or Cooperative Development Authority
(CDA) registration certificate, or other authenticated copy of latest Articles of
Cooperation and other related legal documents;
ii. Co-signers Statement (if applicable);
iii. Copy of latest Income Tax Return;
iv. Mayor’s permit where the business is located;
v. Audited Financial Statements for the past three (3) years preceding the date of
project implementation or in case of those with operation of less than 3 years, for the
years in operation and proof of previous implementation of similar projects (or in the
case of startups, at least for one (1) year);
vi. Document showing that NGO/PO has equity to 20 percent of the total project cost,
which shall be in the form of labor, land for the project site, facilities, equipment and
the like, to be used in the project;
vii. Disclosure of other related business, if any;
viii. List and/or photographs of similar projects previously completed, if any, indicating the
source of funds for implementation;
ix. Sworn affidavit of secretary of the NGO/PO that none of its incorporators, organizers,
directors or officers is an agent of or related by consanguinity or affinity up to the
fourth civil degree to the official of the agency authorized to process and/or approved
the proposed MOA, and release of funds;
h. For CSOs, compliance to regulations as required by the General Appropriations Act (GAA)
pertaining to fund transfers to Civil Society Organizations (CSOs); and
i. For foundations, DOST certification as accredited by the Science and Technology Foundation
Unit
1
required of all proposals
III. Criteria for Evaluation:
A. Criteria for Evaluating Proposals
Criterion
Relevance or Significance
Technical / Scientific Merit
Budget Appropriateness
Competence of Proponent
B. Governing Council / Board and EXECOM’s Evaluation Criteria
Criteria
A. Soundness of Proposal
(20%)
B. Suitability of Output (30%)
C. Significance of Outcome
(30%)
D. Competence of Proponent
(20%)
Definition
Aligned to national S&T priorities, strategic relevance to national
development and sensitivity to Philippine political context, culture,
tradition and gender and development
Sound scientific basis to generate new knowledge or apply existing
knowledge in an innovative manner
The proposed budget is commensurate to the proposed work plan and
deliverables.
Proponent’s expertise is relevant to the proposal and with proven
competence to implement, manage and complete R&D
programs/projects within the approved duration and budget.
Indicators Raw
Score
R&D addresses relevant sectoral need (applicable to 5
pressing concern)
Solution provided is most effective (compared to other 5
proposed solutions)
Proposed budget is reasonable (project is not expensive 5
vis-a-vis output)
Work plan is doable in a given timeframe 5
R&D output is cost-effective (cost is competitive in relation 5
to new or existing products or process)
Has identified partners to adopt the technology (with letter 5
of support from the head of the company)
Output can be commercialized (through an existing 5
manufacturer, spin-off or start-up company)
R&D utilization is timely (output should not be overtaken by 5
other solutions)
Economic: increase in productivity, increase in income, new 5
jobs generated, high return of investment (ROI)
Social: working partnerships established, training 5
opportunities provided, policies adopted, increased access
to basic services (i.e., food, health, education); political,
cultural, gender sensitivity and inclusivity
Environment: enhanced environmental health standards, no 5
adverse effect to the environment
Sustainability: sustainability mechanisms established in 5
terms of institutional, financial and human resources
capability (submission of a new proposal to sustain a
completed or ongoing proposal does not constitute
sustainability of the project)
Proponent's expertise aligned with the proposal 5
Collaboration with relevant agencies and/or industry 5
partners
Thorough understanding of the proposal's deliverables 5
DOST has good experience with the proponent 5
C. Additional Criteria on Gender and Development (GAD)